Filing Flows › Maravai Lifesciences Holdings (MRVI) › Q2 2026 › vs Q2 2025
Maravai Lifesciences Holdings (MRVI) Q2 2026 vs Q2 2025 (year over year)
Maravai Lifesciences Holdings's revenue rose $4.0M (+9%) from $47.4M in Q2 2025 to $51.4M in Q2 2026. The biggest changes: TriLink +$3.6M (+12%); Cygnus +$461K (+3%).
Maravai Lifesciences Holdings, Q2 2026: revenue $51.4M (+8% year over year), operating margin -29.3%, net loss $21.6M, operating cash flow $4.0M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 7.0% | -27.7% | +34.8 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| TriLink | $34.7M | $31.1M | $3.6M | +12% |
| Cygnus | $16.8M | $16.3M | $461K | +3% |
| Revenue | $51.4M | $47.4M | $4.0M | +9% |
| Income tax benefit | $171K | $4.3M | −$4.1M | -96% |
| Net loss | $21.6M | $69.8M | −$48.2M | -69% |
| Costs & expenses | $73.2M | $122M | −$48.3M | -40% |
| Operating costs | $66.5M | $114M | −$47.1M | -41% |
| Interest & other, net | $6.7M | $7.8M | −$1.1M | -14% |
| Cost of revenue | $30.8M | $39.6M | −$8.8M | -22% |
| Research & development | $3.7M | $4.9M | −$1.2M | -24% |
| SG&A | $32.1M | $38.7M | −$6.6M | -17% |
| Operating cash sources | $25.6M | $59.6M | −$33.9M | -57% |
| Depreciation & amortization | $11.8M | $13.2M | −$1.4M | -10% |
| Share-based compensation | $10.2M | $6.8M | $3.4M | +50% |
| Working capital & other | $3.6M | $39.6M | −$36.0M | -91% |
| Net loss absorbed | $21.6M | $69.8M | −$48.2M | -69% |
| Operating cash flow | $4.0M | −$10.3M | $14.3M | — |
| Free cash flow (OCF − capex) | $3.6M | −$13.1M | $16.8M | — |
| Capital expenditures | $370K | $2.9M | −$2.5M | -87% |
Questions
How much did Maravai Lifesciences Holdings's revenue grow year over year in Q2 2026?
Maravai Lifesciences Holdings's revenue rose $4.0M (+9%) from $47.4M in Q2 2025 to $51.4M in Q2 2026.
What drove Maravai Lifesciences Holdings's revenue change in Q2 2026?
TriLink +$3.6M (+12%); Cygnus +$461K (+3%).